16α-(3-fluorobenzyl)-17β-hydroxy-4-methyl-4-aza-5α-androst-1-en-3-one | 564482-05-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 16α-(3-fluorobenzyl)-17β-hydroxy-4-methyl-4-aza-5α-androst-1-en-3-one
• 英文别名: 16alpha-(3-Fluorobenzyl)-17beta-hydroxy-4-methyl-4-aza-5alpha-androst-1-en-3-one；(1S,2S,3aS,3bR,5aR,9aR,9bS,11aS)-2-[(3-fluorophenyl)methyl]-1-hydroxy-6,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,9b,10,11-decahydro-1H-indeno[5,4-f]quinolin-7-one
• CAS: 564482-05-9
• 化学式: C₂₆H₃₄FNO₂
• 分子量: 411.56
• InChiKey: WWYCEUZRECUBAR-NKRFCKFISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  30
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (2S,3aS,3bR,5aR,9aR,9bS,11aS)-2-[(3-fluorophenyl)methyl]-6,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,9b,10,11-decahydroindeno[5,4-f]quinoline-1,7-dione 在 sodium tetrahydroborate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 16α-(3-fluorobenzyl)-17α-hydroxy-4-methyl-4-aza-5α-androst-1-en-3-one 、 16α-(3-fluorobenzyl)-17β-hydroxy-4-methyl-4-aza-5α-androst-1-en-3-one
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of 16-Substituted 4-Azasteroids as Tissue-Selective Androgen Receptor Modulators (SARMs)

  摘要：

  A novel series of 16-substiuted-4-azasteroids has been identified as potential tissue-selective androgen receptor modulators. These ligands display potent hAR binding and agonist activity, low virilizing potential,and good pharmacokinetic profiles in dogs. On the basis of its in vitro profile, 21 was evaluated in the OVX and ORX rat models and exhibited all osteoanabolic, tissue-selective profile.

  DOI：

  10.1021/jm900880r

文献信息

• 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS
  申请人：Merck & Co., Inc.

  公开号：EP1467739A2

  公开（公告）日：2004-10-20
• EP1467739A4
  申请人：——

  公开号：EP1467739A4

  公开（公告）日：2008-01-09
• 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators
  申请人：Dankulich P William

  公开号：US20050107416A1

  公开（公告）日：2005-05-19

  Compounds of structural formula I as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporesis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, arthritis and joint repair, alone or in combination with other active agents.
• US7605152B2
  申请人：——

  公开号：US7605152B2

  公开（公告）日：2009-10-20
• [EN] 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS<br/>[FR] 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES UTILISEES COMME MODULATEURS DU RECEPTEUR D'ANDROGENES
  申请人：MERCK & CO INC

  公开号：WO2003059293A2

  公开（公告）日：2003-07-24

  Compounds of structural formula I as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, arthritis and joint repair, alone or in combination with other active agents.